Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKinsey
Dow
Baxter
Harvard Business School

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,675,611

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,675,611
Title:Methods of providing analgesia
Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C.sub.12/C.sub.max ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
Inventor(s): Oshlack; Benjamin (Boca Raton, FL), Huang; Hua-Pin (Englewood Cliffs, NJ), Masselink; John (Old Tappan, NJ), Tonelli; Alfred (Congers, NY)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:15/376,851
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,675,611
Patent Claims: 1. cited by applicant .
Hansch et al., "Comprehensive Medicinal Chemistry, vol. 5, Biopharmaceutics," Oxford, Pergamon Press, 1990, pp. 251-278. cited by applicant .
Ratain et al., "Population pharmacodynamic study of amonafide: A cancer and leukemia group B study," Journal of Clinical Oncology, Grune and Stratton, 1995, pp. 741-747. cited by applicant .
Database Medline Online! US National Library of Medicine, Yasuhara "Ethnic factors in evaluation of drug efficacy and safety", 1994. cited by applicant .
Setiabudi et al., "Dapsone N-acetylation, Metoprolol, alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonisian population: A cocktail and extended phenotyping assessment trial," Clinical Pharmacology & Therapeutics, 1994, pp. 141-153. cited by applicant .
Database internet "Online!" Helsinki Declaration, 2002. cited by applicant .
English translation of Office Action issued by Japanese Patent Office in connection with corresponding Japanese Patent Application No. 2001-534353 on May 25, 2010. cited by applicant .
Merk Index, 13.sup.th edition, entry 4806: hydrocodone (2001). cited by applicant .
EPI Journal Feb. 2007, pp. 59-60; David Harrison; "Divisional Application a continuing problem" (2007). cited by applicant .
Document CA/PL 17/07; "Misuse of Divisional Applications," by the EPO President, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Oct. 5, 2007. cited by applicant .
Document CA/PL 3/08, presented by epi and other Professional Representatives, addressed to the EPO Committee of Patent Law. Presented at the EPO Administrative Council, dated Feb. 14, 2008. cited by applicant .
Summons to Attend Oral Proceedings issued in connection with European Patent Application No. 05019453.9 on Jul. 23, 2010. cited by applicant .
Abraham Sunshine, et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain," Clin. Pharmacol. Ther., Jun. 1992, pp. 740-746. cited by applicant .
E. Beubler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken," Therapiewoche Osterreich, 7, 2 (1992), pp. 1-15, English translation. cited by applicant .
Geoffrey K. Gourlay, Ph.D., et al., "Influence of a high-fat meal on the absorption of morphine from oral solutions," Clin. Pharmacol. Ther., Oct. 1989, pp. 463-468. cited by applicant .
Robert Kaiko, et al., "A Single-Dose Study of the Effect of Food Ingestion and Timing of Dose Administration on the Pharmacokinetic Profile of 30-MG Sustained-Release Morphine Sulfate Tablets," Current Therapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878. cited by applicant .
Geoffrey K. Gourlay, Ph.D., "The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journal of Pain and Sympton Management, vol. 6., No. 7, Oct. 1991, pp. 431-436. cited by applicant .
Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," The Hospice Journal, vol. 6(4) 1990, pp. 17-30. cited by applicant .
N. Yokokawa, et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J, (1991) 67 (Suppl. 2) pp. S50-S54. cited by applicant .
Physicians Desk Reference 1994, 48.sup.th Edition, pp. 1821-1824. cited by applicant .
D.L. Munday, "Changes in Drug Release Rate 2, Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5.sup.th Cong. Int. Tech. Pharm., 1989, vol. 2, pp. 55-60. cited by applicant .
A Protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol.RTM. to MsContin.RTM. in the Management of Patients with Moderate to Severe Cancer Pain" ("The Protocol"). The date of the Protocol is indicated as Feb. 10, 1992 and it bears COD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, an Australian company. cited by applicant .
Certain Patient Diary Cards, Drug Disposition Records, Case Reports Forms and a listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient, 1992. cited by applicant .
Patient consent forms, apparently for four study participants. cited by other . Investigator Agreements between the study organizers and certain of the principal investigators, 1992. cited by applicant .
Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987. cited by applicant .
Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Journ. of Pain and Sympton Manag., v 4 (3), pp. 146-151, 1989. cited by applicant .
J. Lapin et al., "Guidelines for use of Controlled Release Oral Morphine in Cancer pain Management," Cancer Nursing, v 12 (4), pp. 202-208, 1989. cited by applicant .
R.F. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Purdue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989). cited by applicant .
H.F. Slowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anaesthesia, 1985, vol. 40, pp. 438-440. cited by other .MS Contin--Frequency of Daily Dosing, Jan.-Nov. 1990. cited by applicant .
R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Kapanol.RTM. Capsules Given Every 24 hours and Every 12 hours with MS Confin.RTM. Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain" (1992). cited by applicant .
R.West et al., World Congress on Pain Abstracts 997-1001, Aug. 26, 1993. cited by applicant .
Advertisement: Roxanol SR., 1988 Roxane Labs, Inc. cited by applicant .
R. Kaiko and T. Hunt, Clip. Thera. vol. 13, No. 4, pp. 484-488, 1991. cited by applicant .
S. Bloomfield, et al. Clin. Pharmacol. Ther. vol. 53, No. 4, pp. 469-478, 1993. cited by applicant .
Advertisement: MS Contin 1986, 1987 The Purdue Frederick Company. cited by applicant .
Sustained Release Medications, Noyes Data Corp., pp. 3,4, 10-15, 96-99, 335-337 (1980). cited by applicant .
Flanders, P., et al., "The Control of Drug Release From Conventional Melt Granulation Matrices," Drug Development and Industrial Pharmacy, vol. 13, No. 6, pp. 1001-1022 (1987). cited by applicant .
McTaggart, Celia M., et al., "The evaluation of formulation and processing conditions of a melt granulation process," International Journal of Pharmaceutics, vol. 19, pp. 139-148 (1984). cited by applicant .
Schaefer, T., et al., "Melt granulation in a laboratory scale high shear mixer," Drug Development and Industrial Pharmacy, vol. 16, No. 8.1, pp. 1249-1277 (1990). cited by applicant .
Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables," Drug Development and Industrial Pharmacy, vol. 19, No. 15, pp. 1867-1887 (1993). cited by applicant .
Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets prepared by Melt Pelletization II. Hydrophobic Substances as Meltable Binders," Drug Development and Industrial Pharmacy, vol. 20, No. 77, pp. 1179-1197 (1994). cited by applicant .
Thomsen, L. Juul, "Utilizing melt pelletization technique for the preparation of prolonged release products," Pelletization, (material elaborated by assistant prof. Lars Juul Thomsen, Department of Pharmaceutics, Royal Danish School of Pharmacy for the DIE course "Pelletization Technologh," Nov. 1992, 106 pages plus 3 appendices. cited by applicant .
Maccarrone C. et al.; Single Dose Pharmacokinetics of Kapanol.TM. , a New Oral Sustained-Release Morphine Formulation; Clinical Drug Investigation 1994:7 (5) 262-274. cited by applicant .
West R. J. Maccarrone C. Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol.RTM. capsules. (Abstract 997) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant .
Gourlay GK, Plummer JL, Cherry DA, et al. A comparison of Kapanol.TM. (A new sustained release morphine formulation), MST Continus.RTM. and morphine solution in cancer patients: pharmacokinetic aspects. (Abstract 998) International Association for the Study of Pain, 7.sup.th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant .
Cherry DA, Gourley GK, Plummer JL, et al. A comparison of Kapanol.TM. (a new sustained release morphine formulation), MST Continus.RTM. and morphine solution in cancer patients: morphine metabolite profiles and renal function. (Abstract 999) International Association for the Study of Pain, 7.sup.th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant .
Plummer JL, Cherry DA, Gourlay GK, et al. A comparison of Kapanol.TM. (a new sustained release morphine formulation) MST Continus.RTM. and morphine solution in cancer patients: pharmacodynamic aspects. (Abstract 1000) International Association for the Study of Pain, 7.sup.th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant .
Toner G, Cramond T, Bishop, et al. Randomized double blind, phase III crossover study of a new sustained-release oral morphine formulation, KapanolTM capsules, (Abstract 1001) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant .
European Journal of Cancer; Once a Day (i.e. 24 Hourly) KapanolTM, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles; Part A General Topics 1995; 31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. cited by applicant .
European Journal of Cancer; Kadian.TM./Kapanol.TM.--A Once Daily Morphine Formulation; Part A General Topics 1995; 31 (S5) Suppl: S182 Abs 873 European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. cited by applicant .
Gourlay et al., Proceeding of the 7.sup.th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients: Pharmacokinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management vol. 2 pp. 631-643, 1993. cited by applicant .
Kaiko R.F.; Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient; Anesthesiology and Pain Management 1991, pp. 193-212. cited by applicant .
MS Contin--Frequency of Daily Dosing (NDTI)--Jun. 1991-May 1992. cited by applicant .
The Merck Index, eleventh edition, pp. 757 and 1100 (1989). cited by applicant .
MS Contin--Frequency of Daily Dosing, Jan.-Nov. 1990. cited by applicant .
Encyclopedia of Controlled Drug Delivery, vol. 1, "In vitro-in vivo correlation," pp. 425- 435 (1999). cited by applicant .
Encyclopedia of Controlled Drug Delivery, vol. 2, "Oral drug delivery, small intestine & colon," pp. 698-728 (1999). cited by applicant .
Guidance for Industry, "Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/ In vivo Correlation" ( FDA, 1997). cited by applicant .
Opinion Expressed by the Board of Appeal in the Summons to Oral Proceedings in Case EP02026247 ( May 24, 2011). cited by applicant .
Goodman and Gilman's, The Pharmacological Basis of Therapeutics, pp. 7-8 (1990). cited by applicant .
Office Action issued on May 24, 2011, in connection with European Application No. 10 179 087.1-2123. cited by applicant .
Office Action issued on Jul. 27, 2012, in connection with European Application No. 01 992 565.0-2123. cited by applicant .
Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 177 508.8-2123. cited by applicant .
Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 179 086.3-2123. cited by applicant .
Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 945.7. cited by applicant .
Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 180 984.6. cited by applicant .
Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 181 032.3. cited by applicant .
Zohydro ER Package Insert revised Oct. 2013. cited by applicant .
Advisory Committee Briefing Document, NDA 20-2880, Zohydro.TM. ER Hydrocodone Bitartrate Extended-Release Capsules, Anesthetic and Analgesic Drug Products Advisory Committee, Dec. 7, 2012. cited by applicant .
FDA Response to a Citizen Petition, Docket No. FDA-2013-P-0703, Oct. 25, 2013. cited by applicant .
Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10180984.6. cited by applicant .
Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10181032.3. cited by applicant .
Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10177508.8. cited by applicant .
Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 01992565.0. cited by applicant .
Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179087.1. cited by applicant .
Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179086.3. cited by applicant .
Claims pending in U.S. Appl. No. 13/901,069 on Nov. 22, 2013. cited by applicant .
Claims pending in U.S. Appl. No. 13/901,761 on Nov. 22, 2013. cited by applicant .
Claims pending in U.S. Appl. No. 12/982,386 on Nov. 22, 2013. cited by applicant .
Approval Package for NDA 20-616/5-001 (Kadian.RTM.), 1997. cited by applicant .
Kadian.RTM. Prescribing Information 2006. cited by applicant .
MS Contin.RTM. Prescribing Information 2012. cited by applicant .
Oxycontin.RTM. Prescribing Information 2010. cited by applicant .
Trandemate ER.RTM. PrescribingInformation 2005. cited by applicant .
The Office Action issued in connection with U.S. Appl. No. 12/982,386 on Feb. 26, 2014. cited by applicant .
Benziger, et al., "A Pharmacokinetic/Pharmacodynamic Study of Controlled-Release Oxycodone", 1997. cited by applicant .
Claims pending in U.S. Appl. No. 13/833,263 on Dec. 9, 2013. cited by applicant .
Zohydro ER Hydrocodone Bitartrate Extended-Release (HC-ER) Dec. 7, 2012. cited by applicant .
The Office Action issued in connection with U.S. Appl. No. 13/833,263, on Jun. 23, 2014. cited by applicant .
The Office Action issued in connection with U.S. Appl. No. 14/094,968, on Jun. 23, 2014. cited by applicant .
The Office Action issued in connection with U.S. Appl. No. 12/982,386, on Aug. 13, 2014. cited by applicant .
Santus G., et al., "Osmotic drug delivery: a review of the patent literature," Journal of Controlled Release, vol. 35, No. 1, (1995), pp. 1-21. cited by applicant .
M.H. Beers: "The Merck Index, 11.sup.th edition," 1989, Merck & Co. CP002606249. cited by applicant .
European Search Report issued on Nov. 9, 2010 in connection with European Application No. 10180945.7-2123. cited by applicant .
Advisory Committee Briefing Document, NDA 20/2880, Zohydro.TM. ER Hydrocodone Bitartrate Extended-Release Capsules, Anesthetic and Analgesic Drug Products Advisory Committee, Dec. 7, 2012. cited by applicant .
Claims pending in U.S. Appl. No. 14/210,565 on Mar. 10, 2015. cited by applicant .
Claims pending in U.S. Appl. No. 14/612,483 on Mar. 10, 2015. cited by applicant .
Amendment after final action under 37 C.F.R. .sctn. 1.116 filed in connection with U.S. Appl. No. 11/372,857 on Mar. 2, 2015. cited by applicant .
Declaration under 37 C.F.R. .sctn. 1.132 by Gurvinder Singh Rekhi filed in connection with U.S. Appl. No. 11/372,857 on Mar. 6, 2015. cited by applicant .
Declaration of Interference issued in connection with U.S. Serial Nos. 11/372,857; 13/833,263 and 14/094,968 on Apr. 8, 2015. cited by applicant .
Claims pending in U.S. Appl. No. 14/635,198 on Apr. 14, 2015. cited by applicant .
Claims pending in U.S. Appl. No. 14/672,894 on Apr. 14, 2015. cited by applicant .
Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Containing Certain Active Moieties/Active Ingredients Based on a Biopharmaceutics Classification System (Issued Jan. 1999, Posted Feb. 16, 1999). cited by applicant .
J. W. Barnhart, .et. al., Gas Chromatographic Determination of Hydrocodone in Serum, 130 J. Chromatography 243-49, Abstract (1977). cited by applicant .
Interference 106,022, Paper 6 Oshlack Notice of Related Proceedings, Apr. 22, 2015. cited by applicant .
Interference 106,022, Paper 12 John G. Devane Notice of Related Proceedings, Apr. 22, 2015. cited by applicant .
Interference 106,022, Paper 14 Redeclaration 37 C.F.R. 203(c), Apr. 23, 2015. cited by applicant .
Interference 106,022, Paper 18 Purdue Pharma Motion List, May 7, 2015. cited by applicant .
Interference 106,022, Paper 19 Recro Motion List, May 8, 2015. cited by applicant .
Interference 106,022, Paper 20 Recro Statement Concerning Other Proceedings, May 8, 2015. cited by applicant .
Interference 106,022, Paper 21 Order Authorizing Motions and Setting Times, May 19, 2015. cited by applicant .
Interference 106,022, Paper 22 Redeclaration 37 C.F.R. 41.203(c), May 19, 2015. cited by applicant .
Interference 106,022, Paper 25 Decision Miscellaneous Motion Bd R 121(a)(3), Jul. 2, 2015. cited by applicant .
Interference 106,022, Paper 148 Recro Motion 3, Jul. 10, 2015. cited by applicant .
Interference 106,022, Paper 123 Recro Motion 1, Jul. 10, 2015. cited by applicant .
Interference 106,022, Paper 140 Recro Motion 5, Jul. 10, 2015. cited by applicant .
Interference 106,022, Paper 27 Recro Exhibit List, Jul. 10, 2015. cited by applicant .
Interference 106,022, Paper 142 Purdue Pharma Exhibit List, Jul. 10, 2015. cited by applicant .
Interference 106,022, Paper 143 Purdue Pharma Motion 1, Jul. 10, 2015. cited by applicant .
Interference 106,022, Paper 144 Purdue Pharma Motion 2, Jul. 10, 2015. cited by applicant .
Interference 106,022, Paper 145 Purdue Pharma Motion 4, Jul. 10, 2015. cited by applicant .
Interference 106,022, Paper 152 Order--Responsive Motion, Jul. 24, 2015. cited by applicant .
Interference 106,022, Paper 154 Purdue Motion 5, Jul. 31, 2015. cited by applicant .
Interference 106,022, Paper 163 Recro Motion 6, Jul. 31, 2015. cited by applicant .
Interference 106,022, Paper 159 Recro Updated Exhibit List, Jul. 31, 2015. cited by applicant .
Interference 106,022, Exhibit 2001, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2002, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2003, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2004, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2005, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2006, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2007, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2008, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2009, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2010, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2011, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2012, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2013, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2014, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2015, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2016, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2017, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2018, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2021, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2022, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2023, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2025, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2026, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2027, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2028, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2029, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2030, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2041, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2064, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 2065, Jul. 31, 2015. cited by applicant .
Interference 106,022, Exhibit 2066, Jul. 31, 2015. cited by applicant .
Interference 106,022, Exhibit 2067, Jul. 31, 2015. cited by applicant .
Interference 106,022, Exhibit 2068, Jul. 31, 2015. cited by applicant .
Interference 106,022, Exhibit 2069, Jul. 31, 2015. cited by applicant .
Interference 106,022, Exhibit 2070, Jul. 31, 2015. cited by applicant .
Interference 106,022, Exhibit 2071, Jul. 31, 2015. cited by applicant .
Interference 106,022, Exhibit 1001, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1002, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1003, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1004, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1005, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1006, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1007, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1008, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1009, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1010, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1011, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1012, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1013, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1014, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1015, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1016, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1017, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1019, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1020, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1021, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1022, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1023, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1024, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1025, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1026, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1027, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1028, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1029, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1030, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1041, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1042, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1043, Jul. 10, 2015. cited by applicant .
Interference 106,022, Exhibit 1044, Jul. 10, 2015. cited by applicant .
English translation of the Office Action issued in connection with Japanese Application No. 2014-182108 on Aug. 11, 2015. cited by applicant .
Claims pending in U.S. Appl. No. 14/706,699 on Aug. 21, 2015. cited by applicant .
Claims pending in U.S. Appl. No. 14/727,985 on Aug. 21, 2015. cited by applicant .
Claims pending in U.S. Appl. No. 14/727,997 on Aug. 21, 2015. cited by applicant .
Claims pending in U.S. Appl. No. 14/728,023 on Aug. 21, 2015. cited by applicant .
Interference 106,022, Paper 243: Decision on Motions--37 C.F.R. .sctn. 41.127, Apr. 29, 2016. cited by applicant.

Primary Examiner: Basquill; Sean
Attorney, Agent or Firm: Davidson, Davidson & Kappel, LLC

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Colorcon
McKinsey
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.